Keyphrases
Murine Model
100%
Myeloproliferative Neoplasms
100%
Rigosertib
100%
KRAS Signaling
100%
KRAS G12C
60%
Further Analysis
20%
Phosphorylation
20%
Mouse Model
20%
RAS Gene
20%
Clinical Benefit
20%
Granulocyte Colony-stimulating Factor (G-CSF)
20%
Small Molecules
20%
Phase III Clinical Trial
20%
Childhood Cancer
20%
Disease Treatment
20%
Phase II Clinical Trial
20%
Leukocytosis
20%
Splenomegaly
20%
Malignant Phenotype
20%
Hyperproliferation
20%
Aberrant Signaling
20%
Myeloid Progenitors
20%
Myeloid Malignancies
20%
Small Molecule Therapeutics
20%
Myeloid Disorders
20%
Ras Proteins
20%
Juvenile Myelomonocytic Leukemia
20%
Mx1-Cre
20%
Medicine and Dentistry
Neoplasm
100%
Carcinogenesis
100%
Rigosertib
100%
Diseases
40%
Clinical Trial
20%
In Vitro
20%
Childhood Cancer
20%
Splenomegaly
20%
Myelodysplastic Syndrome
20%
Granulocyte Macrophage Colony Stimulating Factor
20%
Disease
20%
Leukocytosis
20%
Acute Myelogenous Leukemia
20%
Myeloproliferative Disorder
20%
Myeloid Malignancy
20%
Juvenile Myelomonocytic Leukemia
20%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Carcinogenesis
100%
Rigosertib
100%
Diseases
40%
Clinical Trial
20%
Mouse Model
20%
Leukocytosis
20%
Myelodysplastic Syndrome
20%
Splenomegaly
20%
Granulocyte Macrophage Colony Stimulating Factor
20%
Childhood Cancer
20%
Myeloproliferative Disorder
20%
Juvenile Myelomonocytic Leukemia
20%